5-MTHF treatment reduced serum NO, ET-1, IL-6 and TNF-α and increased VEGF in AD rats, perhaps due to the reduced aggregation of Aβ and AS activation, which ameliorates endothelial and synaptic dysfunction [41]. This evidence concerns the gene EDN1 and Alzheimer disease.